Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2023 - Issue 6

Identification and Diagnosis of Possible Mutations in Human P-53 Lymphocytes Download PDF


, , , , , ,
Abstract

This study looked at a few confirmed cases of chronic lymphocytic leukemia (CLL) that may have had mutations in the human B lymphocyte genome's P-53 gene. The ELISA technique was used to determine the frequency of p-53 protein expression in twenty CLL patients undergoing evaluation in stages II–III / IV. In 17 of the 20 cases, the average amounts of p-53 proteins were found to be 16.76 μg/dl, with a probability index of p = 0.034 and a CV of 0.5%. It was discovered that as the illness progressed, the proportion of p-53 positive isoform proteins rose above normal. The percentage was 15% ± 2 in stages 1-2 and 100% in stages 3-4. Recent studies have shown that the p-53 protein inhibits protein kinase B, the AMPK protein, and the mTOR complex, hence mediating genes that trigger autophagy and stimulating autophagy. One potential use of the p-53 protein's role in cancer cell autophagy is the development of a novel anti-cancer medicinal approach. When a patient develops resistance to the initial line of treatment, the ELISA approach has shown to be an invaluable prognostic tool for CLL, enabling the administration of customized medication.

Cite this article
Vancouver
Delia N, Tiberiu T, Cristian MM, Vlad B, Aurelian U, Paula T, et al. Identification and Diagnosis of Possible Mutations in Human P-53 Lymphocytes. Pharmacophore. 2023;14(6):52-8. https://doi.org/10.51847/z8kBl0vAMH
APA
Delia, N., Tiberiu, T., Cristian, M. M., Vlad, B., Aurelian, U., Paula, T., & Stefanita, T. C. T. (2023). Identification and Diagnosis of Possible Mutations in Human P-53 Lymphocytes. Pharmacophore, 14(6), 52-58. https://doi.org/10.51847/z8kBl0vAMH

QR code:

Short Link:
Views: 48

Downloads: 24
Quick Access

Pharmacophore
ISSN: 2229-5402

Pharmacophore
© 2024 All rights reserved
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.